|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
MondayOral cladribine: FDA fast-tracks Serono's oral MS drug - "The Serono Biotech Center is seen in Corsier-sur-Vevey, Switzerland - FULL ARTICLE: "...Fast-track programs are designed to facilitate the development and expedite the review of new drugs that could treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs. Oral cladribine is now eligible for priority review, and the FDA can review data as it is received, instead of waiting until Serono's new drug application is completed...." |